Aytu Total Current Liabilities vs Asset Turnover Analysis

AYTU Stock  USD 1.55  0.10  6.06%   
Aytu BioScience financial indicator trend analysis is way more than just evaluating Aytu BioScience prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aytu BioScience is a good investment. Please check the relationship between Aytu BioScience Total Current Liabilities and its Asset Turnover accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aytu BioScience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Aytu Stock please use our How to Invest in Aytu BioScience guide.

Total Current Liabilities vs Asset Turnover

Total Current Liabilities vs Asset Turnover Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aytu BioScience Total Current Liabilities account and Asset Turnover. At this time, the significance of the direction appears to have strong relationship.
The correlation between Aytu BioScience's Total Current Liabilities and Asset Turnover is 0.6. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Asset Turnover in the same time period over historical financial statements of Aytu BioScience, assuming nothing else is changed. The correlation between historical values of Aytu BioScience's Total Current Liabilities and Asset Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Aytu BioScience are associated (or correlated) with its Asset Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Asset Turnover has no effect on the direction of Total Current Liabilities i.e., Aytu BioScience's Total Current Liabilities and Asset Turnover go up and down completely randomly.

Correlation Coefficient

0.6
Relationship DirectionPositive 
Relationship StrengthSignificant

Total Current Liabilities

Total Current Liabilities is an item on Aytu BioScience balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aytu BioScience are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Asset Turnover

The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.
Most indicators from Aytu BioScience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aytu BioScience current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aytu BioScience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Aytu Stock please use our How to Invest in Aytu BioScience guide.At this time, Aytu BioScience's Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 39.82 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (377.02) in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit52.3M66.6M54.6M57.3M
Total Revenue96.7M107.4M81.0M85.1M

Aytu BioScience fundamental ratios Correlations

0.790.570.940.920.86-0.56-0.720.970.910.970.910.470.760.860.950.910.980.67-0.430.61-0.43-0.260.830.52-0.8
0.790.360.740.750.78-0.42-0.580.830.740.830.740.220.570.680.730.760.740.69-0.70.39-0.7-0.350.690.43-0.79
0.570.360.70.230.450.0-0.950.580.330.40.330.860.810.880.770.610.67-0.04-0.350.94-0.35-0.570.760.79-0.66
0.940.740.70.760.88-0.27-0.830.910.730.890.730.640.740.910.980.970.940.65-0.390.65-0.39-0.530.940.65-0.74
0.920.750.230.760.78-0.74-0.410.890.960.950.960.130.540.610.740.760.870.74-0.350.36-0.350.060.60.22-0.64
0.860.780.450.880.78-0.21-0.590.860.680.90.680.240.510.70.820.960.790.73-0.30.45-0.3-0.50.90.3-0.61
-0.56-0.420.0-0.27-0.74-0.210.13-0.55-0.83-0.56-0.830.07-0.47-0.3-0.34-0.19-0.56-0.270.3-0.240.3-0.56-0.04-0.010.51
-0.72-0.58-0.95-0.83-0.41-0.590.13-0.72-0.5-0.59-0.5-0.86-0.9-0.97-0.89-0.75-0.8-0.170.49-0.880.490.61-0.84-0.830.83
0.970.830.580.910.890.86-0.55-0.720.910.960.910.420.750.840.920.880.960.61-0.440.65-0.44-0.270.840.46-0.8
0.910.740.330.730.960.68-0.83-0.50.910.921.00.210.680.670.760.690.90.6-0.410.49-0.410.110.570.3-0.74
0.970.830.40.890.950.9-0.56-0.590.960.920.920.270.640.740.870.90.920.76-0.390.47-0.39-0.220.790.35-0.73
0.910.740.330.730.960.68-0.83-0.50.911.00.920.210.680.670.760.680.890.6-0.420.49-0.420.110.570.3-0.74
0.470.220.860.640.130.240.07-0.860.420.210.270.210.690.790.690.50.580.03-0.280.7-0.28-0.540.60.9-0.51
0.760.570.810.740.540.51-0.47-0.90.750.680.640.680.690.920.850.640.840.13-0.50.87-0.5-0.330.670.69-0.91
0.860.680.880.910.610.7-0.3-0.970.840.670.740.670.790.920.960.840.910.34-0.520.85-0.52-0.510.870.8-0.88
0.950.730.770.980.740.82-0.34-0.890.920.760.870.760.690.850.960.930.960.54-0.440.75-0.45-0.50.920.7-0.83
0.910.760.610.970.760.96-0.19-0.750.880.690.90.680.50.640.840.930.870.7-0.340.56-0.34-0.570.950.53-0.69
0.980.740.670.940.870.79-0.56-0.80.960.90.920.890.580.840.910.960.870.56-0.440.72-0.44-0.260.820.59-0.82
0.670.69-0.040.650.740.73-0.27-0.170.610.60.760.60.030.130.340.540.70.56-0.3-0.1-0.3-0.20.520.21-0.3
-0.43-0.7-0.35-0.39-0.35-0.30.30.49-0.44-0.41-0.39-0.42-0.28-0.5-0.52-0.44-0.34-0.44-0.3-0.391.00.16-0.32-0.590.67
0.610.390.940.650.360.45-0.24-0.880.650.490.470.490.70.870.850.750.560.72-0.1-0.39-0.39-0.340.690.64-0.72
-0.43-0.7-0.35-0.39-0.35-0.30.30.49-0.44-0.41-0.39-0.42-0.28-0.5-0.52-0.45-0.34-0.44-0.31.0-0.390.16-0.32-0.60.67
-0.26-0.35-0.57-0.530.06-0.5-0.560.61-0.270.11-0.220.11-0.54-0.33-0.51-0.5-0.57-0.26-0.20.16-0.340.16-0.68-0.480.34
0.830.690.760.940.60.9-0.04-0.840.840.570.790.570.60.670.870.920.950.820.52-0.320.69-0.32-0.680.59-0.67
0.520.430.790.650.220.3-0.01-0.830.460.30.350.30.90.690.80.70.530.590.21-0.590.64-0.6-0.480.59-0.6
-0.8-0.79-0.66-0.74-0.64-0.610.510.83-0.8-0.74-0.73-0.74-0.51-0.91-0.88-0.83-0.69-0.82-0.30.67-0.720.670.34-0.67-0.6
Click cells to compare fundamentals

Aytu BioScience Account Relationship Matchups

Aytu BioScience fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets152.8M265.7M137.6M136.5M118.1M124.0M
Other Current Liab14.9M7.4M49.5M55.5M47.5M49.9M
Total Current Liabilities28.3M109.4M64.4M69.0M62.2M65.3M
Total Stockholder Equity95.0M137.6M46.1M39.4M27.7M24.5M
Property Plant And Equipment Net892.6K8.7M6.3M3.9M1.5M1.4M
Net Debt(46.1M)(21.3M)(1.2M)(6.6M)(4.9M)(5.1M)
Retained Earnings(120.0M)(178.3M)(288.5M)(304.1M)(320.0M)(304.0M)
Accounts Payable11.8M19.3M11.0M13.5M10.4M5.4M
Cash48.1M49.6M19.4M23.0M20.0M12.0M
Non Current Assets Total77.9M160.4M77.7M63.6M56.2M31.3M
Cash And Short Term Investments48.1M49.6M19.4M23.0M20.0M12.1M
Common Stock Shares Outstanding226.0K837.3K1.5M3.3M5.5M5.8M
Liabilities And Stockholders Equity152.8M265.7M137.6M136.5M118.1M124.0M
Non Current Liabilities Total29.5M18.7M27.1M28.1M28.2M29.6M
Other Stockholder Equity215.0M315.9M331.4M343.5M347.7M365.1M
Total Liab57.8M128.1M91.5M97.1M90.4M94.9M
Property Plant And Equipment Gross1.2M8.7M6.3M3.9M3.6M3.8M
Total Current Assets75.0M105.2M59.9M72.8M61.9M65.0M
Common Stock Total Equity179.01.8K12.6K3K2.7K2.6K
Other Current Assets5.7M1.0M8.0M8.9M5.6M5.9M
Common Stock12.6K3K4K1K900.0855.0
Net Tangible Assets34.7M(13.7M)(24.5M)(19.6M)(17.7M)(16.8M)
Non Currrent Assets Other33.0K465K766K792K2.2M2.3M
Intangible Assets48.9M85.5M70.6M59.0M52.5M35.8M
Property Plant Equipment258.5K8.7M6.3M3.9M4.4M4.7M
Other Liab28.8M15.9M12.8M13.4M15.4M12.2M
Other Assets33.0K465K766K792K910.8K956.3K
Net Receivables5.2M28.2M21.7M28.9M23.6M24.8M
Inventory10.0M16.3M10.8M12.0M12.6M6.6M
Non Current Liabilities Other18.3M15.9M12.8M7.0M4.5M4.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aytu Stock Analysis

When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.